In breast (Abdelmagid and Too, 2008) and prostate cancers, CPD is upregulated by hormones including prolactin, estrogen, and testosterone, driving oncogenic effects through promoting NO generation and enhancing tumor cell survival (Thomas et al., 2012). The gene discussed is PRL; the disease is prostate carcinoma.